Compounded Semaglutide

Latest four-week snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.

GLP-1 Medications · 1 wave · n=72 answers, pooled

By assistant

How often each assistant brings the brand up in recommendation answers.

Share of recommendations over time

Wave-by-wave share of recommendation answers that named this brand.

What they call it

Recurring descriptions in the assistants' own words, grouped by theme.

• not fda-approved for weight loss alone ×4

  “* *Safety Caveat:* Compounded drugs are **not FDA-approved** for safety and efficacy.”

• dosing errors ×2

  “The FDA says compounded GLP-1s are not reviewed for safety, effectiveness, or quality before marketing; it has also reported dosing errors, hospitalizations, counterfeit labeling concerns, and problems with semaglutide salt forms.”

• unverified quality ×2

  “Avoid buying gray-market or mass-marketed compounded "semaglutide" or "tirzepatide" solely because it is cheap. FDA has warned that non-FDA-approved compounded GLP‑1 products are not equivalent to approved medicines and may not have verified safety, quality, or effectiveness.”

• $5-10 less ×1

  “Compounded Semaglutide and Tirzepatide (The Lowest-Cost Injectables)”

• active ingredient in ozempic and wegovy ×1

  “* **Compounded Semaglutide:** (The active ingredient in Ozempic and Wegovy).”

• additional safety concerns ×1

  “Also, compounded semaglutide operates under different regulatory standards, carrying additional safety concerns like contamination risk from less stringent manufacturing conditions, dosing errors from inconsistent potency, and a lack of clinical trial safety data.”

• adverse-event reports ×1

  “FDA says compounded GLP-1 products are not FDA-approved and warns that some use different salt forms; it has received adverse-event reports involving compounded semaglutide.”

• animal welfare controversies ×1

  “Also, compounded semaglutide operates under different regulatory standards, carrying additional safety concerns like contamination risk from less stringent manufacturing conditions, dosing errors from inconsistent potency, and a lack of clinical trial safety data.”

• avoid as generic substitute ×1

  “Avoid treating "compounded semaglutide" as a generic Rybelsus substitute. FDA says compounded GLP-1 products are not FDA-approved and warns that some use different salt forms; it has received adverse-event reports involving compounded semaglutide.”

• budget-friendly ×1

  “Here are the main ways people find lower-cost options:”

In their words

7 exact quoted mentions in this snapshot, grouped by coded tone.

What they recommend

“with pricing ranging from $99 to $250 per month including the virtual doctor visit”

Where they hedge

“Compounded semaglutide generally costs less than brand-name Ozempic, with prices ranging from $200 to $500 per month depending on the pharmacy and dosage. Some telehealth platforms offer even lower rates — compounded semaglutide costs $199 ”

“Cost: Generally ranges from $200 to $450 per month, inclusive of medical oversight and shipping. *Safety Caveat:* Compounded drugs are **not FDA-approved** for safety and efficacy. If you choose this route, ensure you are working with a lic”

What they warn about

“Avoid buying gray-market or mass-marketed compounded "semaglutide" or "tirzepatide" solely because it is cheap. FDA has warned that non-FDA-approved compounded GLP‑1 products are not equivalent to approved medicines and may not have verifie”

“Be wary of online offers for compounded "Ozempic." Compounded products are **not FDA-approved** and are not generic Ozempic; the FDA has reported dosing errors and other safety/quality concerns, including cases requiring medical attention.”

“It can look cheaper, but it is **not an FDA-approved generic Wegovy**. The FDA says compounded GLP-1s are not reviewed for safety, effectiveness, or quality before marketing; it has also reported dosing errors, hospitalizations, counterfeit”

“Avoid treating "compounded semaglutide" as a generic Rybelsus substitute. FDA says compounded GLP-1 products are not FDA-approved and warns that some use different salt forms; it has received adverse-event reports involving compounded semag”

The substitution map

Which competitors assistants suggest when shoppers ask for something cheaper.

Where this comes from

1 of 7 mentions appear alongside an identifiable web citation. Citation does not establish causation.

Where they send you

Stores and sites assistants name as places to buy this brand.

Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.